Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $4...
ANAVEX®2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS). Therapeutic...
Anavex Life Sciences presented Phase 2b/3 study results at AAIC 2024, showing daily oral blarcamesine (ANAVEX2-73) significantl...
EF Hutton analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $46 price target.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing dif...
EF Hutton analyst Jason Kolbert initiates coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and announces Pri...
